Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Lung Cancer Clinical Trial

Official title:

Immunization of Small Cell Lung Cancer Patients With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01349647
• Other study ID #: 08-095
• Status: Completed
• Phase: Phase 1
• First received: May 5, 2011
• Last updated: January 4, 2016
• Start date: May 2011
• Est. completion date: July 2015

Study information

• Verified date: January 2016
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Even when small cell lung cancer responds well to treatment with chemotherapy, it has a tendency to grow back and to spread. The investigators are interested in testing new therapies aimed at decreasing this risk. This study tests a vaccine, which is a substance injected under the skin which can cause an immune response. The hope is that the body will make antibodies to the vaccine which will also react against the cancer. The vaccine is specific for small cell lung cancer. It combines several components (small cell lung cancer targets) that have been tested individually in patients with small cell lung cancer or other cancers (GD2, GD3, Globo H, Fucosyl GM1 and N-propionylated polysialic acid). Two other substances (KLH and OPT-821) are added which boost the immune system.

This study will have two groups of patients. The first group will receive the vaccines along with one cycle of chemotherapy. The second group will receive the vaccines without chemotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have small cell lung cancer confirmed by the Department of Pathology at Memorial Sloan-Kettering Cancer Center.

• Patients may have limited or extensive stage disease at the time of diagnosis.

• Patients must have completed first-line therapy, with or without thoracic and/or cranial irradiation, and have achieved either a complete response or partial response to therapy without subsequent evidence of disease progression.

• At least 3 weeks must have elapsed between the time the patient completed chemotherapy and the first vaccination.

• No more than 8 weeks can elapse between the time the patient completed chemotherapy and the first vaccination.

• If the patient received thoracic or cranial irradiation after completing the chemotherapy, at least 1 week must have elapsed after the radiation before the first vaccination. Patients must have recovered from the acute toxicities of the radiation prior to starting the vaccine therapy.

• Karnofsky Performance Status > or = to 70%.

• Hematologic parameters:

• WBC > or = to 3.0 x 10^3 cells/µl

• Total lymphocyte count > or = to 0.5 x 10^3 cells/µl

• Platelet count > 100,000/µl

• Biochemical parameters

• Creatinine clearance > or = to 40 ml/min

• Total bilirubin < or = to 1.5 x upper limits of normal

• AST and ALT < or = to 2.5 x upper limits of normal

• Patients must be able to give written informed consent.

• Patients must be = 18 years old.

Exclusion Criteria:

• Patients with progression of disease after first-line chemotherapy.

• Pregnant or lactating women.

• Patients with a history of immunodeficiency or autoimmune disease, or who have undergone radiation to the spleen or splenectomy.

• Patients with a history of leptomeningeal disease.

• Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments.

• Patients with serious unstable medical illness.

• Patients taking systemic corticosteroids.

• Patients with peripheral sensory neuropathy > grade 1.

• Patients who have used non-steroidal anti-inflammatory medications within 2 weeks of vaccination.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lung Cancer

Intervention

Biological:
• vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
• Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Confirm the safety of the pentavalent vaccine in this patient population	After immunization with a pentavalent vaccine, including KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid, with the adjuvant OPT-821. Toxicity will be graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The vaccination will be considered safe if no more than 1 patient has new grade 2 neurotoxicity, grade 3 hepatotoxicity, new autoimmunity or grade 4 local or grade 3 systemic toxicity requiring cessation of treatment.	1 year	Yes
Primary	Confirm the immunogenicity of the pentavalent vaccine in this patient population	an antibody titer of > or = to 1:80 by ELISA against a given antigen or an ELISA titer > or = to 8 fold increase over baseline for patients with a detectable baseline titer; ) confirmation by FACS against tumor cells expressing the four antigens. An increase in percent positive cells by FACS by 3-fold (over 30%) compared to pretreatment level, with the pretreatment level set at 10%, is a positive FACS response.	1 year	No
Secondary	To measure the B-cell response at the cellular level	by generating and analyzing monoclonal antibodies against GD2L, GD3L, Globo H, Fucosyl GM1, and NPropionylated Polysialic Acid and to compare the avidity of the induced antigen specific IgG and IgM antibodies which is not possible with sera	1 year	No
Secondary	To evaluate the use of a circulating tumor cell (CTC) assay in this patient population.	with minimal residual disease to determine if levels correlate with recurrence.	1 year	No

External Links

•   Memorial Sloan Kettering Cancer Center